Long-term Outcome Following Percutaneous Intervention of Intra-stent Coronary Occlusion and Evaluating the Different Treatment Modalities

Overview

Journal Int J Cardiol Heart Vasc

Date 2021 Jul 5

PMID 34222612

Citations 2

Authors

Sandeep Basavarajaiah

Satoru Mitomo

Sunao Nakamura

Vinoda Sharma

Ishaq Mohammed

Yusuke Watanabe

Toru Ouchi

Gurbir Bhatia

Jerome Ment

Sampath Athukorala

Michael Pitt

George Pulikal

Bethan Freestone

Hannah Rides

Nitin Kumar

Richard Watkin

Kaeng Lee

Affiliations

Soon will be listed here.

Abstract

Background: Angioplasty for ISR remains a challenge with relatively high rates of recurrence. Although there is a plethora of data on ISR, there is relatively less data on intra-stent-CTO. In this study, we explore the long-term clinical outcomes following angioplasty to intra-stent CTO and study the differences in clinical outcomes between three treatment-arms: POBA vs. DES vs. DCB.

Methods And Results: We evaluated all patients who underwent PCI to intra-stent CTO between 2011 and 2017. The endpoints used were: cardiac-death, TVMI, TLR, TVR, and MACE.During the study period, 403-patients with a mean age of 69.2 years had successful PCI to intra-stent CTO. 50% were diabetic, 38% had CKD and 32% had left ventricular dysfunction. 93% of cases were stable angina. 22% (n = 88) received only POBA, 28% (n = 113) received DCB and 50% (n = 202) received DES. During the median follow-up of 48-months, cardiac-death occurred in 5.8% (n = 23), TVMI in 4% (n = 16), TLR in 45.6% (n = 182), TVR in 48.7% (n = 194) and MACE of 46%. There were no differences in the hard endpoints between the 3treatment arms. However, the TLR and overall MACE were better in DCB and DES-groups as compared to POBA (TLR: 33%vs.42%vs.49%; p = 0.06); MACE (34% vs. 45% vs. 52%; p = 0.05).

Conclusion: This is the first study that has focussed on the outcomes following angioplasty to intra-stent CTOs with a very long-term follow-up. The hard endpoints were low, although the TLR rates were high. In regards to treatment strategy, the DCB and DES provide relatively better outcomes than POBA.

Citing Articles

Increased long non-coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease.

Zhang X, Kan X, Shen J, Li J J Clin Lab Anal. 2022; 36(11):e24717.

PMID: 36319574 PMC: 9701832. DOI: 10.1002/jcla.24717.

Clinical Outcome of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation for the Treatment of Coronary Drug-Eluting Stent In-Stent Chronic Total Occlusion.

Zhang Y, Wu Z, Wang S, Liu T, Liu J Cardiovasc Drugs Ther. 2022; 37(6):1155-1166.

PMID: 35930211 PMC: 10721670. DOI: 10.1007/s10557-022-07363-7.

References

Latib A, Mussardo M, Ielasi A, Tarsia G, Godino C, Al-Lamee R . Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc Interv. 2011; 4(2):155-64. DOI: 10.1016/j.jcin.2010.09.027. View

Zocca P, Kok M, Tandjung K, Danse P, Jessurun G, Hautvast R . 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial. JACC Cardiovasc Interv. 2018; 11(5):462-469. DOI: 10.1016/j.jcin.2017.11.031. View

Christopoulos G, Karmpaliotis D, Alaswad K, Lombardi W, Grantham J, Rangan B . The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: insights from a US multicenter registry. Catheter Cardiovasc Interv. 2014; 84(4):646-51. PMC: 4148463. DOI: 10.1002/ccd.25465. View

Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Jensen C . Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. J Am Coll Cardiol. 2020; 75(21):2664-2678. DOI: 10.1016/j.jacc.2020.04.006. View

Stone G, Midei M, Newman W, Sanz M, Hermiller J, Williams J . Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary.... Circulation. 2009; 119(5):680-6. DOI: 10.1161/CIRCULATIONAHA.108.803528. View

Cutlip D, Windecker S, Mehran R, Boam A, Cohen D, van Es G . Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344-51. DOI: 10.1161/CIRCULATIONAHA.106.685313. View

Luscher T, Steffel J, Eberli F, Joner M, Nakazawa G, Tanner F . Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007; 115(8):1051-8. DOI: 10.1161/CIRCULATIONAHA.106.675934. View

Azzalini L, Dautov R, Ojeda S, Benincasa S, Bellini B, Giannini F . Procedural and Long-Term Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusion. JACC Cardiovasc Interv. 2017; 10(9):892-902. DOI: 10.1016/j.jcin.2017.01.047. View

Byrne R, Neumann F, Mehilli J, Pinieck S, Wolff B, Tiroch K . Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2012; 381(9865):461-7. DOI: 10.1016/S0140-6736(12)61964-3. View

10.

Alfonso F, Perez-Vizcayno M, Cuesta J, Garcia Del Blanco B, Garcia-Touchard A, Lopez-Minguez J . 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents. JACC Cardiovasc Interv. 2018; 11(10):981-991. DOI: 10.1016/j.jcin.2018.02.037. View

11.

Kufner S, Joner M, Schneider S, Tolg R, Zrenner B, Repp J . Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. JACC Cardiovasc Interv. 2017; 10(13):1332-1340. DOI: 10.1016/j.jcin.2017.04.024. View

12.

Mehran R, Dangas G, Abizaid A, Mintz G, Lansky A, Satler L . Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999; 100(18):1872-8. DOI: 10.1161/01.cir.100.18.1872. View

13.

Takasawa Y, Iijima R, Shiba M, Nakamura M, Sugi K . Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention. J Cardiol. 2010; 55(3):391-6. DOI: 10.1016/j.jjcc.2010.01.003. View

14.

Scheller B, Clever Y, Kelsch B, Hehrlein C, Bocksch W, Rutsch W . Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012; 5(3):323-30. DOI: 10.1016/j.jcin.2012.01.008. View

15.

Neumann F, Sousa-Uva M . 'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization. Eur Heart J. 2019; 40(2):79-80. DOI: 10.1093/eurheartj/ehy855. View

16.

Stolker J, Kennedy K, Lindsey J, Marso S, Pencina M, Cutlip D . Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circ Cardiovasc Interv. 2010; 3(4):327-34. DOI: 10.1161/CIRCINTERVENTIONS.110.946939. View

17.

Rittger H, Brachmann J, Sinha A, Waliszewski M, Ohlow M, Brugger A . A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012; 59(15):1377-82. DOI: 10.1016/j.jacc.2012.01.015. View

18.

de la Torre Hernandez J, Rumoroso J, Subinas A, Gonzalo N, Ojeda S, Pan M . Percutaneous intervention in chronic total coronary occlusions caused by in-stent restenosis: procedural results and long-term clinical outcomes in the TORO (Spanish registry of chronic TOtal occlusion secondary to an occlusive in-stent RestenOsis).... EuroIntervention. 2016; 13(2):e219-e226. DOI: 10.4244/EIJ-D-16-00764. View

19.

Dangas G, Claessen B, Caixeta A, Sanidas E, Mintz G, Mehran R . In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010; 56(23):1897-907. DOI: 10.1016/j.jacc.2010.07.028. View

20.

Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H . Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv. 2011; 4(2):149-54. DOI: 10.1016/j.jcin.2010.10.012. View